Atossa Therapeutics Inc (ATOS)

Currency in USD
2.3600
-0.0600(-2.48%)
Closed·
2.2670-0.0930(-3.94%)
·
Advertisement
ATOS is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
2.24002.4500
52 wk Range
1.700019.3500
Key Statistics
Prev. Close
2.42
Open
2.37
Day's Range
2.24-2.45
52 wk Range
1.7-19.35
Volume
78.02K
Average Volume (3m)
150.25K
1-Year Change
-80.0085%
Book Value / Share
3.12
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
ATOS Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
22.0000
Upside
+832.20%
Members' Sentiments
Bearish
Bullish
ProTips
Quickly burning through cash

Atossa Therapeutics Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Buy
Moving Averages
Strong Buy

Analyst Ratings

2 Buy
0 Hold
0 Sell
Ratings:
2 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 22.0000
(+832.20% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
Rodman & Renshaw
Buy12.00+408.47%-New Coverage07/07/2026
H.C. Wainwright
Buy25.00+959.32%7.00Maintain27/03/2026
Craig-Hallum
Buy10.00+323.73%35.00Maintain12/02/2026
Craig-Hallum
Buy35.00+1,383.05%60.00Maintain04/02/2026
Ascendiant Capital
Buy8.00+238.98%7.75Maintain08/12/2025

Atossa Therapeutics Inc Earnings Call Summary for Q4/2024

  • Atossa Genetics Q4 2024 EPS of -0.04 beats -0.065 forecast; stock up 0.47% to $0.752
  • Net loss reduced to $25.5M from $30.1M in 2023; operating expenses down to $27.6M from $31.4M
  • Cash position strong at $71.1M; company prioritizing Zendoxifen development for breast cancer
  • FDA consultations expected in 4-6 months; U.S. market focus with global expansion planned for 2026
  • Analyst price targets range $4-$7; company maintains "Fair" financial health score of 2.45/5
Last Updated: 25/03/2025, 14:10
Read Full Transcript

Earnings

Latest Release
07/08/2026
EPS / Forecast
-0.95 / -1.05
Revenue / Forecast
-- / --
EPS Revisions
Last 90 days

Compare ATOS to Peers and Sector

Metrics to compare
ATOS
Peers
Sector
Relationship
P/E Ratio
−0.5x−2.6x−0.4x
PEG Ratio
0.02−0.040.00
Price/Book
0.8x2.0x2.6x
Price / LTM Sales
-9.6x3.0x
Upside (Analyst Target)
-95.4%48.7%
Fair Value Upside
Unlock3.9%5.6%Unlock

Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops medicines in areas of significant unmet medical need in oncology in the United States. Its lead drug candidate is oral (Z)-endoxifen, a selective estrogen receptor modulator and selective estrogen receptor degrader currently in Phase 2 clinical development for the treatment and reduction of risk of breast cancer, as well as in other therapeutic areas. The company was formerly known as Atossa Genetics Inc. and changed its name to Atossa Therapeutics, Inc. in January 2020. Atossa Therapeutics, Inc. was founded in 2008 and is based in Seattle, Washington.

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
761.83K8.85%1.80M
Other Institutional Investors
907.71K10.54%2.14M
Public Companies & Retail Investors
6.94M80.61%16.38M
Total
8.61M100.00%20.32M

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
Vanguard Capital Management, LLC4.66%401,331947
Heights Capital Management, Inc.4.38%377,500891

People Also Watch

0.0730
BINI
+12.31%
2.100
ANY
-6.25%
7.0000
AKTX
-13.37%
0.652
KNDI
-6.72%
1.220
FRSX
-1.61%

FAQ

What Is the Atossa Therapeutics (NASDAQ: ATOS) Share Price Today?

The Atossa Therapeutics stock price today is 2.3600 USD.

What Stock Exchange Does Atossa Therapeutics (ATOS) Trade On?

Atossa Therapeutics is listed and trades on the Nasdaq Stock Exchange.

What Is the Ticker (Stock Symbol) for Atossa Therapeutics?

The stock symbol (also called a 'ticker') for Atossa Therapeutics is "ATOS."

What Is the Current Atossa Therapeutics Market Capitalisation?

As of today, Atossa Therapeutics (NASDAQ: ATOS) market cap is 20.8400M USD.

What Is Atossa Therapeutics's (ATOS) Earnings Per Share (TTM)?

The Atossa Therapeutics EPS is currently -4.3700 (Trailing Twelve Months).

When Is the Next Atossa Therapeutics Earnings Date?

Atossa Therapeutics's next earnings report will be released on 16/11/2026.

Is ATOS a Buy or Sell From a Technical Analyst Perspective?

Based on today's Atossa Therapeutics moving averages and other technical indicators, the daily buy/sell signal for ATOS stock is Neutral.

How Many Times Has Atossa Therapeutics Stock Split?

Atossa Therapeutics has split 3 times. (See the ATOS stock split history page for full effective split date and price information.)

How Many Employees Does Atossa Therapeutics Have?

Atossa Therapeutics has 16 employees, based on their latest Companies House report.

What is the current trading status of Atossa Therapeutics (NASDAQ: ATOS)?

As of 08/08/2026, Atossa Therapeutics (ATOS) is trading at a share price of 2.3600 USD, with a previous close of 2.4200 USD. The stock has fluctuated within a day range of 2.2400 USD to 2.4500 USD, while its 52-week range spans from 1.7000 USD to 19.3500 USD.

What Is Atossa Therapeutics (ATOS) Price Target According to Analysts?

The average 12-month price target for Atossa Therapeutics is 22.0000 USD, with a high estimate of 24 USD and a low estimate of 20 USD. 2 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +832.20% Upside potential.

What Is the ATOS Premarket Price?

ATOS's last pre-market stock price is 2.4997 USD. The pre-market share volume is 2,560.0000, and the stock has decreased by 0.0797, or 3.2900%.

What Is the ATOS After Hours Price?

ATOS's last after hours stock price is 2.2670 USD, the stock has decreased by -0.0930, or -3.9400%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.